Connolly EA, Boye K, Bonvalot S, Kratz CP, Leithner A, Malkin D, Messiou C, Miah AB, Pantziarka P, Timmermann B, van der Graaf WTA, Thomas DM, Stacchiotti S (2025)
Genetic predisposition in sarcomas: clinical implications and management
EClinicalMedicine, 83, 103203
DOI 10.1016/j.eclinm.2025.103203, PubMed 40291347

Yip D, Zalcberg J, Blay JY, Eriksson M, Espinoza D, Price T, Marreaud S, Italiano A, Steeghs N, Boye K, Underhill C, Gebski V, Simes J, Gelderblom H, Joensuu H (2025)
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Br J Cancer (in press)
DOI 10.1038/s41416-025-02983-w, PubMed 40133509

Berner K, Hernes E, Kvassheim M, Revheim ME, Bastiansen J, Selboe S, Bakken CL, Grønningsæter SR, Bruland ØS, Larsen RH, Bouzelmat L, Jardine VL, Stokke C (2025)
First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted ²¹²Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer
J Nucl Med, 66 (5), 732-738
DOI 10.2967/jnumed.124.269299, PubMed 40081958